TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2864962
Drug: Phosphatidylcholine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine (30 g/day)
Study: 29056072
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (Intervention)
Study: 27809796
Drug: 8-week web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week web-based stress management intervention (STREAM) with weekly written feedback by a psychologist
Study: 20136803
Drug: Vacuum interferential
Normalized name: thymol
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vacuum interferential current (IFC) therapy
Study: 12826548
Drug: Postoperative local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative local anesthetics and supplemental analgesics
Study: 9864004
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 100 microg once daily
Study: 9864004
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 200 microg once daily
Study: 9864004
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 100 microg twice daily
Study: 1442757
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 to 40 mg/d)
Study: 3910296
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 280 mg mefloquine, 800 mg sulfadoxine and 40 mg pyrimethamine
Study: 3910296
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 420 mg mefloquine, 1200 mg sulfadoxine and 60 mg pyrimethamine
Study: 3910296
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1500 mg sulfadoxine and 75 mg pyrimethamine
Study: 18076041
Drug: Highest quintile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quintile of triglycerides (>/=160 mg/dl)
Study: 18076041
Drug: Lowest quintile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest quintile of HDL (<30 mg/dl)
Study: 15309442
Drug: Rye bran
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rye bran breads (10.2 mg ferulic acid per day)
Study: 9223886
Drug: Albumin and
Normalized name: Bovine serum albumin and glutaraldehyde only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin and lactated Ringer solution (Group III)
Study: 8267190
Drug: Open-label continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label continuous epidural infusion of clonidine (10-50 micrograms/h)
Study: 28951026
Drug: Coping partnership
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping partnership intervention (1 home visit, weekly telephone calls for month 1, biweekly calls for months 2 and 3)
Study: 17074300
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy (CBT) in RCT (N=30)
Study: 17074300
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy (CBT) in routine practice (N=384)
Study: 12099542
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% three times daily for 12 weeks
Study: 12099542
Drug: Acetazolamide 250-mg
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250-mg q.i.d. for 12 weeks
Study: 10847958
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of gas flow through the perfusate before bypass, starting FIO2 of 0.80
Study: 10847958
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of gas flowing through the perfusate, starting FIO2 of 0.21
Study: 8678268
Drug: glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glucose solution + lipid emulsion
Study: 8678268
Drug: fructose solution
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fructose solution + lipid emulsion
Study: 1964153
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (1000 mg/m2 cyclophosphamide, 50 mg/m2 doxorubicin, 1.4 mg/m2 vincristine)
Study: 1964153
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy using three different drug-combinations (A: 1500 mg/m2 cyclophosphamide, 100 mg/m2 lomustine, 15 mg/m2 methotrexate; B: 1000 mg/m2 cyclophosphamide, 40 mg/m2 doxorubicin, 1 mg/m2 vincristine; C: 5 x 1.6 g/m2 ifosfamide plus mesna, 5 x 120 mg/m2 etopside)
Study: 1964153
Drug: Surgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery followed by chemotherapy and radiotherapy
Study: 418984
Drug: Monistat Cream
Normalized name: Monistat
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Monistat Cream for 7 days
Study: 418984
Drug: Monistat Cream
Normalized name: Monistat
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Monistat Cream for 14 days
Study: 30520013
Drug: 12 infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 infusions of rituximab (375 mg/m2) in combination with CHOEP chemotherapy
Study: 30520013
Drug: 6 infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 infusions of rituximab (375 mg/m2) in combination with CHOEP chemotherapy (control group)
Study: 22209640
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication (individualized dose of psychostimulants such as methylphenidate or dextroamphetamine/amphetamine combination)
Study: 15314858
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin administration in doses exceeding routine ones
Study: 11889659
Drug: Tailored self-care
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored self-care treatment program
Study: 11889659
Drug: Usual TMD
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual TMD treatment
Study: 9797623
Drug: Morphine (n=62)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (n=62)
Study: 9797623
Drug: Non-morphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-morphine treatment (n=33)
Study: 2378776
Drug: Propofol (1.34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.34 mg/kg of LTM for ED50, 2.56 mg/kg of LTM for ED95)
Study: 334609
Drug: Butacote, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butacote, 200 mg b.d. for four weeks
Study: 334609
Drug: Naproxen, 250
Normalized name: Naproxen, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, 250 mg b.d. for four weeks
Study: 19185773
Drug: GoChi (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GoChi (120 mL/d)
Study: 10197889
Drug: Adjunctive megavitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive megavitamin and dietary treatment
Study: 10197889
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 25 mg vitamin C and allergenic substances
Study: 8527549
Drug: Rifabutin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (600 mg/d) in combination with ethambutol, streptomycin, and clarithromycin (500 mg b.i.d.)
Study: 8527549
Drug: Rifabutin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (600 mg/d) in combination with ethambutol, streptomycin, and azithromycin (600 mg/d)
Study: 7948562
Drug: Rifabutin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (600 mg/d)
Study: 2273082
Drug: Methyldopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (250 mg tid) for 14 days
Study: 7378251
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Phyllocontin Continus tablets and salbutamol)
Study: 30677187
Drug: Usual basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual basal insulin dose
Study: 30677187
Drug: Reduced (75%)
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced (75%) basal insulin dose
Study: 23449126
Drug: Topical enzymatically
Normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical enzymatically generated hydrogen peroxide (using glucose oxidase and glucose)
Study: 19811710
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% diltiazem hydrochloride, applied perianally twice daily for 8 weeks
Study: 19811710
Drug: 0.2% glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% glyceryl trinitrate (GTN), applied perianally twice daily for 8 weeks
Study: 15079108
Drug: Hypertonic colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic colloid solution (250 ml of 7.2% NaCl/6% Hydroxyethylstarch)
Study: 15079108
Drug: Usual Ringer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Ringer solution (control group)
Study: 11679441
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of nitroglycerin (GTN) at 1 microg.kg(‐1).min(‐1) for 4 hours
Study: 7524141
Drug: alfuzosin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfuzosin 2.5 mg TID
Study: 30113638
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment 1 mg/m2/d (≈0.035 mg/kg/d)
Study: 23963307
Drug: Drospirenone 0.25
Normalized name: drospirenone 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 0.25 mg/17β‐estradiol 0.5 mg
Study: 23963307
Drug: Drospirenone 0.5
Normalized name: drospirenone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 0.5 mg/17β‐estradiol 0.5 mg
Study: 23963307
Drug: 17β‐estradiol 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17β‐estradiol 0.3 mg
Study: 18952561
Drug: 4 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 courses of anthracycline-based chemotherapy followed by 4 courses of docetaxel or paclitaxel in combination with trastuzumab, followed by 14 additional courses of trastuzumab (total of 18 doses)
Study: 18952561
Drug: 3 courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 courses of 3-weekly docetaxel in combination with weekly trastuzumab (total of 9 doses) followed by 3 courses of 5-fluorouracil/epirubicin/cyclophosphamide
Study: 10861325
Drug: Bacille Calmette‐Guérin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacille Calmette‐Guérin vaccine
Study: 8971495
Drug: Phosphocreatine (PCr)
Normalized name: phosphocysteamine
DrugBank: Phosphocreatine (DB13191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphocreatine (PCr) administration
Study: 18675744
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic NaCl solution)
Study: 30352784
Drug: Selinexor (60,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (60, 80, or 100 mg orally) plus bortezomib (1.3 mg/m2 subcutaneously) and dexamethasone (20 mg orally) once or twice weekly in 21- or 35-day cycles.
Study: 30352784
Drug: Selinexor (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (100 mg once weekly), bortezomib (1.3 mg/m2 once weekly for 4 weeks), and dexamethasone (40 mg once weekly) per 35-day cycle (recommended phase 2 dose).
Study: 22919238
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin administered immediately after ERCP
Study: 12214938
Drug: Artemether (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether (1.6 mg/kg body wt., repeated after 12 hrs and then daily for four days)
Study: 12214938
Drug: Quinine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (10 mg/kg body wt in 10 ml/kg body wt of 5% dextrose in 0.9% saline intravenously, repeated every 8 hrs and changed to oral administration when the child was able to drink to finish seven days)
Study: 7740949
Drug: Oral cefadroxil
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefadroxil
Study: 2633082
Drug: CP-enriched cardioplegia
Normalized name: methylcellulose (1500 CPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-enriched cardioplegia at a concentration of 10 mmol/l
Study: 26601565
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream
Study: 25581584
Drug: Fluorouracil cream
Normalized name: Fluorouracil Cream
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil cream
Study: 17941858
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (up to 105 mg/day)
Study: 17941858
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (over 90 mg/day)
Study: 15001200
Drug: Olmesartan medoxomil/HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil/HCTZ 20/12.5 mg
Study: 15001200
Drug: Olmesartan medoxomil/HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil/HCTZ 40/25 mg
Study: 9787943
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) at a dose of 2 g/d
Study: 12589521
Drug: Buspirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (30 mg orally)
Study: 2475681
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil (240-mg tablets), given once or twice daily
Study: 367715
Drug: Syndol (analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syndol (analgesic combination)
Study: 28668970
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression (IPC) for 2 weeks, 6 hours daily bilateral calf IPC applied under an orthosis on the injured side.
Study: 28668970
Drug: Treatment-as-usual (plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (plaster cast without IPC) for 2 weeks.
Study: 30952794
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium 220 mg twice daily
Study: 29066877
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin (200 IU/day)
Study: 10386278
Drug: Succinylcholine 1
Normalized name: Succinylcholine 124 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1 to 1.5 mg/kg
Study: 1763654
Drug: Clonidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (300 micrograms daily)
Study: 1763654
Drug: Bromocryptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocryptine (5 mg daily)
Study: 26607249
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite (80 or 160 mg/day, capsules, TheraVasc)
Study: 21457066
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (GLU)
Study: 21457066
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (ASP)
Study: 22240636
Drug: Pomegranate seed
Normalized name: pomegranate seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate seed oil (PGS) 30 mg, 127 μg of steroidal phytoestrogens per dose, taken twice daily for 12 weeks
Study: 18575579
Drug: D3 receptor‐preferring
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 receptor‐preferring agonist pramipexole
Study: 10454450
Drug: EPA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (4 g/d)
Study: 2185155
Drug: Clavulanate‐potentiated amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clavulanate‐potentiated amoxicillin (Augmentin)
Study: 26558386
Drug: Transcranial direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial direct current stimulation combined with constraint-induced movement therapy
Study: 26558386
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation with constraint-induced movement therapy
Study: 19432500
Drug: TZP-101 single
Normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TZP-101 single doses (160-600 microg/kg)
Study: 19432500
Drug: TZP-101 multiple
Normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TZP-101 multiple doses (80-600 microg/kg/day)
Study: 16143120
Drug: Certolizumab 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certolizumab 100 mg
Study: 16143120
Drug: Certolizumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certolizumab 400 mg (in patients with baseline C-reactive protein levels of 10 mg/L or greater)
Study: 16143120
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in patients with baseline C-reactive protein levels of 10 mg/L or greater)
Study: 11865831
Drug: Pentoxifylline (PXF)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PXF) 1600 mg daily
Study: 10206296
Drug: 5‐Fluorouracil (5FU)‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐Fluorouracil (5FU)‐based chemotherapy
Study: 2159990
Drug: Desciclovir, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desciclovir, 250 mg three times a day for 14 days
Study: 18212314
Drug: Chlorthalidone (diuretic)
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (diuretic)
Study: 18212314
Drug: Doxazosin (alpha-blocker)
Normalized name: ALPHA BLOCKERS/RELATED
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxazosin (alpha-blocker)
Study: 27084978
Drug: USL255 (topiramate
Approvals — FDA: no, EMA: no, PMDA: no
Description: USL255 (topiramate extended-release capsules) up to 400 mg/day
Study: 23909985
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/day plus pioglitazone 15 mg
Study: 23909985
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/day plus pioglitazone 30 mg
Study: 23909985
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/day plus pioglitazone 45 mg
Study: 23909985
Drug: All combination-treated
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All combination-treated groups
Study: 22419733
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment during euglycemic-hyperinsulinemic clamp
Study: 22419733
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment during hyperglycemic-hyperinsulinemic clamp
Study: 22419733
Drug: High glucose
Normalized name: ONE TOUCH HIGH GLUCOSE CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: High glucose and insulin treatment in monocytes
Study: 21287477
Drug: Lidocaine 5%
Normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 5% (75 mg) and 10 micrograms sufentanil
Study: 21287477
Drug: Lidocaine 5%
Normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 5% (75 mg) and 5 micrograms sufentanil
Study: 21287477
Drug: Lidocaine 5%
Normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 5% (75 mg) and 2 ml of normal saline (control group)
Study: 18385198
Drug: Temsirolimus i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus i.v. 25 mg weekly
Study: 18385198
Drug: Temsirolimus i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus i.v. 15 mg weekly plus interferon s.c. 6 MU thrice weekly
Study: 18385198
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (IFN) s.c. up to 18 MU thrice weekly
Study: 11813224
Drug: Anti-lymphocyte antibody
Normalized name: lymphocyte immune globulin, anti-thymocyte globulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-lymphocyte antibody induction therapy
Study: 8566881
Drug: Levosulpiride (LS)
Normalized name: bisoprolol fumarate Oral Tablet [Emcor LS]
DrugBank: Levosulpiride (DB16021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride (LS) regimen (higher dose on day 8)
Study: 8566881
Drug: Metoclopramide (MTC)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MTC) regimen (higher dose on day 8)
Study: 2147736
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg norgestrel + (Cyclo‐Progynova)
Study: 2147736
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg cyproterone acetate (SH D 461 A)
Study: 31016671
Drug: Gentamicin 5
Normalized name: gentamicin 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 5 mg/kg based on lean body weight in morbidly obese individuals
Study: 31016671
Drug: Gentamicin 5
Normalized name: gentamicin 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 5 mg/kg based on total body weight in non-obese individuals
Study: 22761551
Drug: Constraint induced
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint induced movement therapy (CIMT)
Study: 19562243
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment of osteoporosis (control group)